Healthcare / BiotechnologyShenzhen
$16.44
+0.52 (+3.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $135.8M · quality 65.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.0B
P/E
42.2x
↑EV/EBITDA
26.0x
↑ROE
9.3%
↑Gross Margin
85.9%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.6%
FCF CAGR
-12.6%
FCF margin
24.2%
FCF / Net income
1.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $364.1M · net income $82.4M · FCF $88.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $364.1M | $364.1M | $363.2M | $413.7M | $433.2M |
| Net Income | $82.4M | $82.4M | $134.6M | $191.0M | $185.4M |
| EBITDA | $110.9M | $110.9M | $175.0M | $238.9M | $231.2M |
| EPS | 0.46 | 0.46 | 0.75 | 1.06 | 1.28 |
| Gross Margin | 85.9% | 85.9% | 87.6% | 89.9% | 88.7% |
| Operating Margin | 20.8% | 20.8% | 37.0% | 46.6% | 47.4% |
| Net Margin | 22.6% | 22.6% | 37.1% | 46.2% | 42.8% |
| Balance Sheet | |||||
| Current Ratio | 8.42 | 8.42 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $88.1M | $88.1M | $135.8M | $148.6M | $131.8M |
| Returns | |||||
| ROE | 9.3% | 9.3% | 15.1% | 20.1% | 21.4% |
| Valuation | |||||
| P/E | 42.15 | 42.15 | 26.67 | 25.58 | 34.06 |
| EV/EBITDA | 25.99 | 25.99 | 19.85 | 20.13 | 26.96 |
| P/B | 3.31 | 3.31 | 4.04 | 5.15 | 7.30 |
| Growth & Yield | |||||
| Revenue Growth | 0.3% | 0.3% | -12.2% | -4.5% | — |
| EPS Growth | -38.7% | -38.7% | -29.2% | -17.2% | — |
| Dividend Yield | 1.7% | 1.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
46.9%
EPS terminal req.
$1.46
Spread vs growth
-85.6%
5Y implied EPS CAGR
30.9%
EPS terminal req.
$1.77
Spread vs growth
-69.5%
10Y implied EPS CAGR
20.0%
EPS terminal req.
$2.84
Spread vs growth
-58.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-15.9%
Start / end P/E
26.6x → 35.7x
EPS bridge
0.75 → 0.46
Residual
-13.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.